Cited by 35Cancer, Hypoxia, and MetabolismCancer Immunotherapy and BiomarkersImmune cells in cancer

CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes

Open access
Labiano, Sara, Meléndez-Rodríguez, Florinda, Palazón, Asís, Teijeira, Álvaro, Garasa, Saray, Etxeberria, Iñaki, Aznar, M. Ángela, Sánchez-Paulete, Alfonso R. +9 more·2017·OncoImmunology

Abstract

CD69 is an early activation marker on the surface of T lymphocytes undergoing activation by cognate antigen. We observed intense expression of CD69 on tumor-infiltrating T-lymphocytes that reside in the hypoxic tumor microenvironment and hypothesized that CD69 could be, at least partially, under the control of the transcriptional hypoxia response. In line with this, human and mouse CD3-stimulated lymphocytes cultured under hypoxia (1% O2) showed increased expression of CD69 at the protein and mRNA level. Consistent with these findings, mouse T lymphocytes that had recently undergone hypoxia in vivo, as denoted by pimonidazole staining, were more frequently CD69+ in the tumor and bone marrow hypoxic tissue compartments. We found evidence for HIF-1α involvement both when using T-lymphocytes from inducible HIF-1α−/− mice and when observing tumor-infiltrating T-lymphocytes in mice whose T cells are HIF-1α−/−. Direct pro-transcriptional activity of HIF-1α on a newly identified hypoxia response element (HRE) found in the human CD69 locus was demonstrated by ChIP experiments. These results uncover a connection between the HIF-1α oxygen-sensing pathway and CD69 immunobiology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2017.1283468

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Labiano, S., Meléndez-Rodríguez, F., Palazón, A., Teijeira, Á., Garasa, S., Etxeberria, I., Aznar, M. Á., Sánchez-Paulete, A. R., Azpilikueta, A., Bolaños, E., Molina, C., de la Fuente, H., Maiso, P., Sánchez-Madrid, F., de Landázuri, M. O., Aragonés, J., & Melero, I.
Affiliations
  • Navarre Institute of Health Research (ES)
  • Research Unit, Santa Cristina Hospital, Research Institute Princesa (IP), Autonomous University of Madrid, Madrid, Spain
  • University of Cambridge (GB)
  • Immunology and Immunotherapy Department, Center for Applied Medical Research (CIMA) and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain
  • Department of Vascular Biology and Inflammation, National Center for Cardiovascular Research (CNIC), Madrid, Spain
  • Hospital Universitario Santa Cristina (ES)
Corresponding author
Melero, Ignacio
Venue
OncoImmunology
Published
2017-01-19
Volume
6
Issue
4
Pages
e1283468
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2574645689
Cited by
35
References
51
Citations by year
2026: 4 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 1
FWCI
0.64
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Comunidad de Madrid (S2010/BMD-2542, INDISNET-S2011/BMD-2332, RD 12-0042-0056)
  • Ministerio de Economía y Competitividad (SAF 2014-52361-R, SAF2014-55579R, SAF2013-46058-R, S2011/BMD-2332, SAF2011-22831)
  • Banco Bilbao Vizcaya Argentaria
  • Gobierno de Navarra
  • Instituto de Salud Carlos III
  • European Social Fund
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
CD69, HIF-1α, hypoxia, tumor-infiltrating T cells, hypoxia response element, transcriptional regulation, oxygen sensing, T cell activation, tumor microenvironment, pimonidazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review